These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 24879295)

  • 1. Hepatitis C NS5A protein: two drug targets within the same protein with different mechanisms of resistance.
    Lim PJ; Gallay PA
    Curr Opin Virol; 2014 Oct; 8():30-7. PubMed ID: 24879295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combinations of two drugs among NS3/4A inhibitors, NS5B inhibitors and non-selective antiviral agents are effective for hepatitis C virus with NS5A-P32 deletion in humanized-liver mice.
    Doi A; Hikita H; Kai Y; Tahata Y; Saito Y; Nakabori T; Yamada R; Kodama T; Sakamori R; Murayama A; Nitta S; Asahina Y; Suemizu H; Tatsumi T; Kato T; Takehara T
    J Gastroenterol; 2019 May; 54(5):449-458. PubMed ID: 30684016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of NS5A inhibitors against unusual and potentially difficult-to-treat HCV subtypes commonly found in sub-Saharan Africa and South East Asia.
    Nguyen D; Smith D; Vaughan-Jackson A; Magri A; ; Barnes E; Simmonds P
    J Hepatol; 2020 Oct; 73(4):794-799. PubMed ID: 32470499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Daclatasvir-like inhibitors of NS5A block early biogenesis of hepatitis C virus-induced membranous replication factories, independent of RNA replication.
    Berger C; Romero-Brey I; Radujkovic D; Terreux R; Zayas M; Paul D; Harak C; Hoppe S; Gao M; Penin F; Lohmann V; Bartenschlager R
    Gastroenterology; 2014 Nov; 147(5):1094-105.e25. PubMed ID: 25046163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis C virus activity without detectable cross-resistance.
    Chatterji U; Garcia-Rivera JA; Baugh J; Gawlik K; Wong KA; Zhong W; Brass CA; Naoumov NV; Gallay PA
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3327-34. PubMed ID: 24687498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world.
    Pérez AB; Chueca N; García-Deltoro M; Martínez-Sapiña AM; Lara-Pérez MM; García-Bujalance S; Aldámiz-Echevarría T; Vera-Méndez FJ; Pineda JA; Casado M; Pascasio JM; Salmerón J; Alados-Arboledas JC; Poyato A; Téllez F; Rivero-Juárez A; Merino D; Vivancos-Gallego MJ; Rosales-Zábal JM; García F;
    J Hepatol; 2019 Nov; 71(5):876-888. PubMed ID: 31279901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of polymorphisms with significant resistance to NS5A inhibitors in treatment-naive patients with hepatitis C virus genotypes 1a and 3a in Sweden.
    Lindström I; Kjellin M; Palanisamy N; Bondeson K; Wesslén L; Lannergard A; Lennerstrand J
    Infect Dis (Lond); 2015 Aug; 47(8):555-62. PubMed ID: 25851241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct binding of ledipasvir to HCV NS5A: mechanism of resistance to an HCV antiviral agent.
    Kwon HJ; Xing W; Chan K; Niedziela-Majka A; Brendza KM; Kirschberg T; Kato D; Link JO; Cheng G; Liu X; Sakowicz R
    PLoS One; 2015; 10(4):e0122844. PubMed ID: 25856426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Daclatasvir inhibits hepatitis C virus NS5A motility and hyper-accumulation of phosphoinositides.
    Chukkapalli V; Berger KL; Kelly SM; Thomas M; Deiters A; Randall G
    Virology; 2015 Feb; 476():168-179. PubMed ID: 25546252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel substitution in NS5A enhances the resistance of hepatitis C virus genotype 3 to daclatasvir.
    Fernandes Campos GR; Ward J; Chen S; Bittar C; Vilela Rodrigues JP; Martinelli ALC; Souza FF; Pereira LRL; Rahal P; Harris M
    J Gen Virol; 2021 Jan; 102(1):. PubMed ID: 33141008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C virus NS5A inhibitors and drug resistance mutations.
    Nakamoto S; Kanda T; Wu S; Shirasawa H; Yokosuka O
    World J Gastroenterol; 2014 Mar; 20(11):2902-12. PubMed ID: 24659881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resensitizing daclatasvir-resistant hepatitis C variants by allosteric modulation of NS5A.
    Sun JH; O'Boyle DR; Fridell RA; Langley DR; Wang C; Roberts SB; Nower P; Johnson BM; Moulin F; Nophsker MJ; Wang YK; Liu M; Rigat K; Tu Y; Hewawasam P; Kadow J; Meanwell NA; Cockett M; Lemm JA; Kramer M; Belema M; Gao M
    Nature; 2015 Nov; 527(7577):245-8. PubMed ID: 26536115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fast hepatitis C virus RNA elimination and NS5A redistribution by NS5A inhibitors studied by a multiplex assay approach.
    Liu D; Ji J; Ndongwe TP; Michailidis E; Rice CM; Ralston R; Sarafianos SG
    Antimicrob Agents Chemother; 2015; 59(6):3482-92. PubMed ID: 25845863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A retrospective study of the efficacy of sofosbuvir plus NS5A inhibitors for patients with hepatitis C virus genotype-2 chronic infection.
    Lv DD; Wang ML; Chen EQ; Wu DB; Tao YC; Zhang DM; Tang H
    Eur J Gastroenterol Hepatol; 2019 Mar; 31(3):382-388. PubMed ID: 30383554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect on hepatitis C virus replication of combinations of direct-acting antivirals, including NS5A inhibitor daclatasvir.
    Pelosi LA; Voss S; Liu M; Gao M; Lemm JA
    Antimicrob Agents Chemother; 2012 Oct; 56(10):5230-9. PubMed ID: 22850513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Daclatasvir: potential role in hepatitis C.
    Lee C
    Drug Des Devel Ther; 2013; 7():1223-33. PubMed ID: 24204123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant HCV variants with NS5A from genotypes 1-7 have different sensitivities to an NS5A inhibitor but not interferon-α.
    Scheel TK; Gottwein JM; Mikkelsen LS; Jensen TB; Bukh J
    Gastroenterology; 2011 Mar; 140(3):1032-42. PubMed ID: 21111742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Self-association and conformational variation of NS5A domain 1 of hepatitis C virus.
    Beldar S; Manimekalai MSS; Cho NJ; Baek K; Grüber G; Yoon HS
    J Gen Virol; 2018 Feb; 99(2):194-208. PubMed ID: 29300159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical Profile and Clinical Efficacy of a Novel Hepatitis C Virus NS5A Inhibitor, EDP-239.
    Owens CM; Brasher BB; Polemeropoulos A; Rhodin MH; McAllister N; Peng X; Wang C; Ying L; Cao H; Lawitz E; Poordad F; Rondon J; Box TD; Zeuzem S; Buggisch P; Lin K; Qiu YL; Jiang L; Colvin R; Or YS
    Antimicrob Agents Chemother; 2016 Oct; 60(10):6207-15. PubMed ID: 27503640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5A.
    Wang C; Jia L; Huang H; Qiu D; Valera L; Huang X; Sun JH; Nower PT; O'Boyle DR; Gao M; Fridell RA
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1588-90. PubMed ID: 22203595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.